Characteristics of originator-naïve and originator-experienced switchers at the time of GP1111 switch, stratified by indication
| Originator-naïve switchers, N=1171 | Originator-experienced switchers, N=434 | |||||
| RA* | PsA | AxSpA | RA* | PsA | AxSpA | |
| Number of patients, n | 482 | 244 | 445 | 203 | 70 | 161 |
| Female, n (%) | 327 (68) | 127 (52) | 155 (35) | 147 (72) | 26 (37) | 36 (22) |
| Age, years | 59 (47–67) | 51 (40–58) | 42 (32–51) | 66 (55–74) | 56 (50–65) | 51 (43–58) |
| Disease duration, years | 7 (4–14) | 7 (4–12) | 4 (3–7) | 20 (14–27) | 16 (12–25) | 18 (12–25) |
| 0–5 years, n (%) | 178 (38) | 81 (36) | 266 (63) | 0 (0) | <5 | 0 (0) |
| >5 years, n (%) | 291 (62) | 142 (64) | 159 (37) | 194 (100) | 67 (99) | 159 (100) |
| BMI, kg/m2 | 25.2 (22.2–29.4) | 28.1 (23.8–31.2) | 26.1 (23.1–28.7) | 24.3 (21.9–28.2) | 26.3 (23.8–28.7) | 25.2 (22.8–27.8) |
| Current smoking, n (%) | 119 (25) | 45 (19) | 125 (28) | 42 (21) | 17 (24) | 49 (31) |
| Year of originator treatment start | ||||||
| 2000–2004, n (%) | – | – | – | 51 (25) | 6 (9) | 28 (17) |
| 2005–2009, n (%) | 105 (52) | 44 (63) | 93 (58) | |||
| 2010–2015, n (%) | 47 (23) | 20 (28) | 40 (25) | |||
| Prior originator treatment duration, years | – | – | – | 8 (6–11) | 7 (5–9) | 8 (6–10) |
| Prior CT-P13 treatment duration, years | 1 (1–3) | 1 (1–3) | 1 (1–3) | 4 (4–4) | 4 (4–4) | 4 (4–4) |
| Concomitant MTX, n (%) | 354 (73) | 134 (55) | 52 (12) | 163 (81) | 48 (69) | 33 (21) |
| Prior non-infliximab bDMARD treatments, n (%) | ||||||
| 0 | 324 (67) | 163 (67) | 314 (70) | 134 (66) | 51 (73) | 113 (70) |
| 1 | 84 (17) | 48 (20) | 65 (15) | 37 (18) | 11 (16) | 25 (16) |
| ≥2 | 74 (15) | 33 (14) | 66 (15) | 32 (16) | 8 (11) | 23 (14) |
| Visits during 1 year follow-up | 3 (2–6) | 3 (2–7) | 3 (2–7) | 3 (2–6) | 2 (2–5) | 3 (2–6) |
| Disease activity | ||||||
| In DAS28/ASDAS remission†, n (%) | 215 (45) | 135 (55) | 128 (29) | 123 (61) | 43 (61) | 56 (35) |
| In CDAI/ASDAS remission‡, n (%) | 193 (40) | 102 (42) | 128 (29) | 86 (42) | 27 (39) | 56 (35) |
| CRP, mg/L | 3 (1–6) | 2 (1–4) | 2 (1–4) | 2 (1–3) | 2 (1–4) | 2 (1–3) |
| DAS28 | 2.3 (1.8–3.2) | 2.1 (1.7–2.9) | – | 1.9 (1.4–2.4) | 2.0 (1.6–2.5) | – |
| CDAI | 5.6 (2.3–9.7) | 5.2 (2.0–9.5) | – | 2.9 (1.4–5.8) | 4.1 (2.1–7.4) | – |
| BASDAI, mm | – | – | 27.5 (12.7–51.2) | – | – | 22.7 (6.3–36.8) |
| BASFI | – | – | 20.8 (8.2–45.5) | – | – | 22.3 (8.9–41.5) |
| ASDAS | – | – | 1.8 (1.1–2.8) | – | – | 1.5 (0.9–2.3) |
| Physician global VAS, mm | 6 (2–13) | 6 (2–11) | 5 (2–8) | 5 (2–9) | 3 (1–11) | 3 (1–11) |
| Patient pain VAS, mm | 27 (12–54) | 31 (9–57) | 22 (8–50) | 19 (8–38) | 24 (9–45) | 20 (7–36) |
| Patient fatigue VAS, mm | 44 (22–68) | 52 (19–76) | 45 (18–70) | 28 (12–58) | 31 (17–59) | 29 (11–52) |
| Patient global VAS, mm | 36 (13–60) | 37 (17–68) | 27 (10–55) | 21 (8–49) | 22 (10–46) | 23 (8–42) |
| HAQ | 0.6 (0.1–1.1) | 0.8 (0.1–1.1) | 0.4 (0.0–0.8) | 0.5 (0.1–1.1) | 0.4 (0.0–1.0) | 0.3 (0–0.6) |
| PASS yes, n (%) | 270 (56) | 130 (53) | 267 (60) | 138 (68) | 48 (69) | 104 (65) |
| Comorbidities§ | ||||||
| Cancer, n (%) | 10 (2) | 7 (3) | 6 (1) | 5 (2) | <5 | <5 |
| Hospitalised infection, n (%) | 132 (28) | 58 (24) | 80 (18) | 64 (32) | 19 (27) | 36 (22) |
| Knee/hip prosthesis, n (%) | 50 (11) | 11 (5) | 11 (3) | 21 (10) | <5 | 6 (4) |
| Pulmonary disease, n (%) | 28 (6) | 16 (7) | 14 (3) | 16 (8) | <5 | 1 (0.5) |
| Diabetes, n (%) | 26 (5) | 15 (6) | 9 (2) | 14 (7) | 6 (9) | 11 (7) |
| Myocardial infarction, n (%) | 10 (2) | <5 | <5 | 7 (3) | <5 | 5 (3) |
| Chronic kidney disease, n (%) | 9 (2) | <5 | <5 | <5 | <5 | <5 |
Numbers are median (IQRs) unless otherwise stated. Baseline is time window from 90 days before to 6 days after switch date (baseline). Patient pain (VAS 0–100), fatigue (VAS 0–100), patient global assessment (VAS 0–100) and physician global VAS 0–100. For patient discretion, numbers below 5 are not presented.
*Also includes 55 patients with Juvenile RA, polyarthritis, reactive arthritis and other arthritis.
†DAS28/ASDAS remission defined as DAS28 <2.6 (RA and PsA), ASDAS <1.3 (AxSpA).
‡CDAI remission defined as <2.9 (RA and PsA).
§0–10 years prior to baseline and ever for cancer.
ASDAS, Ankylosing Spondylitis Disease Activity Score; AxSpA, axial spondyloarthritis ; BASDAI, Bath Ankylosing Spondylitis (BAS) Disease Activity Index; BASFI, BAS Functional Index; bDMARD, biologic disease-modifying anti-rheumatic drug; BMI, body mass index; CDAI, Clinical Disease Activity Index; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; MTX, methotrexate; PASS, Patient Acceptable Symptom State; PsA, psoriatic arthritis ; RA, rheumatoid arthritis ; VAS, Visual Analogue Scale.